Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 47

1.

Cost Effectiveness of Interval Cytoreductive Surgery With Hyperthermic Intraperitoneal Chemotherapy in Stage III Ovarian Cancer on the Basis of a Randomized Phase III Trial.

Koole SN, van Lieshout C, van Driel WJ, van Schagen E, Sikorska K, Kieffer JM, Schagen van Leeuwen JH, Schreuder HWR, Hermans RH, de Hingh IH, van der Velden J, Arts HJ, Massuger LFAG, Aalbers AG, Verwaal VJ, Van de Vijver KK, Aaronson NK, van Tinteren H, Sonke GS, van Harten WH, Retèl VP.

J Clin Oncol. 2019 Aug 10;37(23):2041-2050. doi: 10.1200/JCO.19.00594. Epub 2019 Jun 28.

PMID:
31251694
2.

Health-related quality of life after interval cytoreductive surgery with or without hyperthermic intraperitoneal chemotherapy (HIPEC) in patients with stage III ovarian cancer.

Koole SN, Kieffer JM, K Sikorska, Schagen van Leeuwen JH, Schreuder HWR, Hermans RH, de Hingh IH, van der Velden J, Arts HJ, van Ham MAPC, Aalbers AG, Verwaal VJ, Van de Vijver KK, Sonke GS, van Driel WJ, Aaronson NK.

Eur J Surg Oncol. 2019 May 13. pii: S0748-7983(19)30444-5. doi: 10.1016/j.ejso.2019.05.006. [Epub ahead of print] Review.

PMID:
31128948
3.

Reasons for low uptake of a psychological intervention offered to cancer survivors with elevated depressive symptoms.

van der Donk LJ, Tovote KA, Links TP, Roodenburg JLN, Kluin-Nelemans JC, Arts HJG, Mul VEM, van Ginkel RJ, Baas PC, Hoff C, Sanderman R, Fleer J, Schroevers MJ.

Psychooncology. 2019 Apr;28(4):830-838. doi: 10.1002/pon.5029. Epub 2019 Mar 5. Erratum in: Psychooncology. 2019 Sep;28(9):1942.

4.

Age should not be a limiting factor in laparoscopic surgery: a prospective multicenter cohort study on quality of life after laparoscopic hysterectomy.

Briët JM, Mourits MJ, van Leeuwen BL, van den Heuvel ER, Kenkhuis MJ, Arts HJ, de Bock GH.

Clin Interv Aging. 2018 Dec 13;13:2517-2526. doi: 10.2147/CIA.S172965. eCollection 2018.

5.

Hyperthermic Intraperitoneal Chemotherapy in Ovarian Cancer.

van Driel WJ, Koole SN, Sikorska K, Schagen van Leeuwen JH, Schreuder HWR, Hermans RHM, de Hingh IHJT, van der Velden J, Arts HJ, Massuger LFAG, Aalbers AGJ, Verwaal VJ, Kieffer JM, Van de Vijver KK, van Tinteren H, Aaronson NK, Sonke GS.

N Engl J Med. 2018 Jan 18;378(3):230-240. doi: 10.1056/NEJMoa1708618.

6.

The impact of centralization of services on treatment delay in ovarian cancer: A study on process quality.

Eggink FA, Vermue MC, Van der Spek C, Arts HJ, Apperloo MJ, Nijman HW, Niemeijer GC.

Int J Qual Health Care. 2017 Oct 1;29(6):810-816. doi: 10.1093/intqhc/mzx107.

PMID:
29025074
7.

Volume-controlled versus short drainage after inguinofemoral lymphadenectomy in vulvar cancer patients: A Dutch nationwide prospective study.

Pouwer AW, Hinten F, van der Velden J, Smolders RGV, Slangen BFM, Zijlmans HJMAA, IntHout J, van der Zee AGJ, Boll D, Gaarenstroom KN, Arts HJ, de Hullu JA.

Gynecol Oncol. 2017 Sep;146(3):580-587. doi: 10.1016/j.ygyno.2017.06.031. Epub 2017 Jul 4.

PMID:
28687171
8.

Cost-effectiveness of laparoscopy as diagnostic tool before primary cytoreductive surgery in ovarian cancer.

van de Vrie R, van Meurs HS, Rutten MJ, Naaktgeboren CA, Opmeer BC, Gaarenstroom KN, van Gorp T, Ter Brugge HG, Hofhuis W, Schreuder HWR, Arts HJG, Zusterzeel PLM, Pijnenborg JMA, van Haaften M, Engelen MJA, Boss EA, Vos MC, Gerestein KG, Schutter EMJ, Kenter GG, Bossuyt PMM, Mol BW, Buist MR.

Gynecol Oncol. 2017 Sep;146(3):449-456. doi: 10.1016/j.ygyno.2017.06.019. Epub 2017 Jun 20.

PMID:
28645428
9.

Limiting the morbidity of inguinofemoral lymphadenectomy in vulvar cancer patients; a review.

Pouwer AW, Arts HJ, van der Velden J, de Hullu JA.

Expert Rev Anticancer Ther. 2017 Jul;17(7):615-624. doi: 10.1080/14737140.2017.1337513. Epub 2017 Jun 13. Review.

PMID:
28608762
10.

Laparoscopy to Predict the Result of Primary Cytoreductive Surgery in Patients With Advanced Ovarian Cancer: A Randomized Controlled Trial.

Rutten MJ, van Meurs HS, van de Vrie R, Gaarenstroom KN, Naaktgeboren CA, van Gorp T, Ter Brugge HG, Hofhuis W, Schreuder HW, Arts HJ, Zusterzeel PL, Pijnenborg JM, van Haaften M, Fons G, Engelen MJ, Boss EA, Vos MC, Gerestein KG, Schutter EM, Opmeer BC, Spijkerboer AM, Bossuyt PM, Mol BW, Kenter GG, Buist MR.

J Clin Oncol. 2017 Feb 20;35(6):613-621. doi: 10.1200/JCO.2016.69.2962. Epub 2016 Dec 28.

PMID:
28029317
11.

Molecular imaging in ovarian cancer.

Reyners AK, Broekman KE, Glaudemans AW, Brouwers AH, Arts HJ, van der Zee AG, de Vries EG, Jalving M.

Ann Oncol. 2016 Apr;27 Suppl 1:i23-i29. doi: 10.1093/annonc/mdw091. Review.

PMID:
27141066
12.

CD103 defines intraepithelial CD8+ PD1+ tumour-infiltrating lymphocytes of prognostic significance in endometrial adenocarcinoma.

Workel HH, Komdeur FL, Wouters MC, Plat A, Klip HG, Eggink FA, Wisman GB, Arts HJ, Oonk MH, Mourits MJ, Yigit R, Versluis M, Duiker EW, Hollema H, de Bruyn M, Nijman HW.

Eur J Cancer. 2016 Jun;60:1-11. doi: 10.1016/j.ejca.2016.02.026. Epub 2016 Mar 31.

PMID:
27038842
13.

Treatment Regimen, Surgical Outcome, and T-cell Differentiation Influence Prognostic Benefit of Tumor-Infiltrating Lymphocytes in High-Grade Serous Ovarian Cancer.

Wouters MC, Komdeur FL, Workel HH, Klip HG, Plat A, Kooi NM, Wisman GB, Mourits MJ, Arts HJ, Oonk MH, Yigit R, de Jong S, Melief CJ, Hollema H, Duiker EW, Daemen T, de Bruyn M, Nijman HW.

Clin Cancer Res. 2016 Feb 1;22(3):714-24. doi: 10.1158/1078-0432.CCR-15-1617. Epub 2015 Sep 18.

14.

Folate Receptor-Beta Has Limited Value for Fluorescent Imaging in Ovarian, Breast and Colorectal Cancer.

de Boer E, Crane LM, van Oosten M, van der Vegt B, van der Sluis T, Kooijman P, Low PS, van der Zee AG, Arts HJ, van Dam GM, Bart J.

PLoS One. 2015 Aug 6;10(8):e0135012. doi: 10.1371/journal.pone.0135012. eCollection 2015.

15.

Stopping ovarian cancer screening in BRCA1/2 mutation carriers: effects on risk management decisions & outcome of risk-reducing salpingo-oophorectomy specimens.

van Driel CM, de Bock GH, Arts HJ, Sie AS, Hollema H, Oosterwijk JC, Mourits MJ.

Maturitas. 2015 Mar;80(3):318-22. doi: 10.1016/j.maturitas.2014.12.009. Epub 2014 Dec 30.

PMID:
25600260
16.

Assessment of estrogen receptor expression in epithelial ovarian cancer patients using 16α-18F-fluoro-17β-estradiol PET/CT.

van Kruchten M, de Vries EF, Arts HJ, Jager NM, Bongaerts AH, Glaudemans AW, Hollema H, de Vries EG, Hospers GA, Reyners AK.

J Nucl Med. 2015 Jan;56(1):50-5. doi: 10.2967/jnumed.114.147579. Epub 2014 Dec 4.

17.

Radical surgery in patients with residual disease after (chemo)radiation for cervical cancer.

Boers A, Arts HJ, Klip H, Nijhuis ER, Pras E, Hollema H, Wisman GB, Nijman HW, Mourits MJ, Reyners AK, de Bock GH, Thomas G, van der Zee AG.

Int J Gynecol Cancer. 2014 Sep;24(7):1276-85. doi: 10.1097/IGC.0000000000000171.

PMID:
24987914
18.

Cytoreductive surgery followed by chemotherapy versus chemotherapy alone for recurrent platinum-sensitive epithelial ovarian cancer (SOCceR trial): a multicenter randomised controlled study.

van de Laar R, Zusterzeel PL, Van Gorp T, Buist MR, van Driel WJ, Gaarenstroom KN, Arts HJ, van Huisseling JC, Hermans RH, Pijnenborg JM, Schutter EM, Pelikan HM, Vollebergh JH, Engelen MJ, Inthout J, Kruitwagen RF, Massuger LF.

BMC Cancer. 2014 Jan 14;14:22. doi: 10.1186/1471-2407-14-22.

19.

Positron emission tomography imaging of oestrogen receptor-expression in endometrial stromal sarcoma supports oestrogen receptor-targeted therapy: case report and review of the literature.

van Kruchten M, Hospers GA, Glaudemans AW, Hollema H, Arts HJ, Reyners AK.

Eur J Cancer. 2013 Dec;49(18):3850-5. doi: 10.1016/j.ejca.2013.08.005. Epub 2013 Sep 2. Review.

PMID:
24007820
20.

Less gastrointestinal toxicity after adjuvant radiotherapy on a small pelvic field compared to a standard pelvic field in patients with endometrial carcinoma.

de Jong RA, Pras E, Boezen HM, van der Zee AG, Mourits MJ, Arts HJ, Aalders JG, Slot A, Timmer PR, Hollema H, Nijman HW.

Int J Gynecol Cancer. 2012 Sep;22(7):1177-86. doi: 10.1097/IGC.0b013e31826302dd.

PMID:
22854651
21.

Laparoscopy to predict the result of primary cytoreductive surgery in advanced ovarian cancer patients (LapOvCa-trial): a multicentre randomized controlled study.

Rutten MJ, Gaarenstroom KN, Van Gorp T, van Meurs HS, Arts HJ, Bossuyt PM, Ter Brugge HG, Hermans RH, Opmeer BC, Pijnenborg JM, Schreuder HW, Schutter EM, Spijkerboer AM, Wensveen CW, Zusterzeel P, Mol BW, Kenter GG, Buist MR.

BMC Cancer. 2012 Jan 20;12:31. doi: 10.1186/1471-2407-12-31.

22.

Intraoperative tumor-specific fluorescence imaging in ovarian cancer by folate receptor-α targeting: first in-human results.

van Dam GM, Themelis G, Crane LM, Harlaar NJ, Pleijhuis RG, Kelder W, Sarantopoulos A, de Jong JS, Arts HJ, van der Zee AG, Bart J, Low PS, Ntziachristos V.

Nat Med. 2011 Sep 18;17(10):1315-9. doi: 10.1038/nm.2472.

PMID:
21926976
23.

The effect of chemotherapy on expression of folate receptor-alpha in ovarian cancer.

Crane LM, Arts HJ, van Oosten M, Low PS, van der Zee AG, van Dam GM, Bart J.

Cell Oncol (Dordr). 2012 Feb;35(1):9-18. doi: 10.1007/s13402-011-0052-6. Epub 2011 Jun 7. Erratum in: Cell Oncol (Dordr). 2012 Jun;35(3):229.

24.

Laparoscopic hysterectomy is preferred over laparotomy in early endometrial cancer patients, however not cost effective in the very obese.

Bijen CB, de Bock GH, Vermeulen KM, Arts HJ, ter Brugge HG, van der Sijde R, Kraayenbrink AA, Bongers MY, van der Zee AG, Mourits MJ.

Eur J Cancer. 2011 Sep;47(14):2158-65. doi: 10.1016/j.ejca.2011.04.035. Epub 2011 Jun 1.

25.

Cost effectiveness of laparoscopy versus laparotomy in early stage endometrial cancer: a randomised trial.

Bijen CB, Vermeulen KM, Mourits MJ, Arts HJ, Ter Brugge HG, van der Sijde R, Wijma J, Bongers MY, van der Zee AG, de Bock GH.

Gynecol Oncol. 2011 Apr;121(1):76-82. doi: 10.1016/j.ygyno.2010.11.043. Epub 2011 Jan 6.

PMID:
21215439
26.

Intraoperative near-infrared fluorescence imaging for sentinel lymph node detection in vulvar cancer: first clinical results.

Crane LM, Themelis G, Arts HJ, Buddingh KT, Brouwers AH, Ntziachristos V, van Dam GM, van der Zee AG.

Gynecol Oncol. 2011 Feb;120(2):291-5. doi: 10.1016/j.ygyno.2010.10.009. Epub 2010 Nov 6.

PMID:
21056907
27.

Implementing an advanced laparoscopic procedure by monitoring with a visiting surgeon.

Briët JM, Mourits MJ, Kenkhuis MJ, van der Zee AG, de Bock GH, Arts HJ.

J Minim Invasive Gynecol. 2010 Nov-Dec;17(6):771-8. doi: 10.1016/j.jmig.2010.05.011.

PMID:
20955987
28.

Intraoperative multispectral fluorescence imaging for the detection of the sentinel lymph node in cervical cancer: a novel concept.

Crane LM, Themelis G, Pleijhuis RG, Harlaar NJ, Sarantopoulos A, Arts HJ, van der Zee AG, Ntziachristos V, van Dam GM.

Mol Imaging Biol. 2011 Oct;13(5):1043-9. doi: 10.1007/s11307-010-0425-7. Erratum in: Mol Imaging Biol. 2011 Oct;13(5):1050. Vasilis, Ntziachristos [corrected to Ntziachristos, Vasilis].

29.

Safety of laparoscopy versus laparotomy in early-stage endometrial cancer: a randomised trial.

Mourits MJ, Bijen CB, Arts HJ, ter Brugge HG, van der Sijde R, Paulsen L, Wijma J, Bongers MY, Post WJ, van der Zee AG, de Bock GH.

Lancet Oncol. 2010 Aug;11(8):763-71. doi: 10.1016/S1470-2045(10)70143-1. Epub 2010 Jul 16.

PMID:
20638901
30.

Short-term surgical outcome and safety of risk reducing salpingo-oophorectomy in BRCA1/2 mutation carriers.

Kenkhuis MJ, de Bock GH, Elferink PO, Arts HJ, Oosterwijk JC, Jansen L, Mourits MJ.

Maturitas. 2010 Jul;66(3):310-4. doi: 10.1016/j.maturitas.2010.03.018. Epub 2010 Apr 21.

PMID:
20409655
31.

Spontaneous disappearance of suspected intrapulmonary metastases after hysterectomy in a patient with a complete hydatiform mole.

Knol HM, Arts HJ, Reyners AK.

Gynecol Oncol. 2010 Mar;116(3):580-1. doi: 10.1016/j.ygyno.2009.10.066. Epub 2009 Nov 17. No abstract available.

PMID:
19922991
32.

Expression of epidermal growth factor receptor (EGFR) and activated EGFR predict poor response to (chemo)radiation and survival in cervical cancer.

Noordhuis MG, Eijsink JJ, Ten Hoor KA, Roossink F, Hollema H, Arts HJ, Pras E, Maduro JH, Reyners AK, de Bock GH, Wisman GB, Schuuring E, van der Zee AG.

Clin Cancer Res. 2009 Dec 1;15(23):7389-97. doi: 10.1158/1078-0432.CCR-09-1149. Epub 2009 Nov 17.

33.

The prognostic value of TRAIL and its death receptors in cervical cancer.

Maduro JH, Noordhuis MG, ten Hoor KA, Pras E, Arts HJ, Eijsink JJ, Hollema H, Mom CH, de Jong S, de Vries EG, de Bock GH, van der Zee AG.

Int J Radiat Oncol Biol Phys. 2009 Sep 1;75(1):203-11. doi: 10.1016/j.ijrobp.2009.03.071.

PMID:
19695437
34.

Total laparoscopic hysterectomy versus abdominal hysterectomy in the treatment of patients with early stage endometrial cancer: a randomized multi center study.

Bijen CB, Briët JM, de Bock GH, Arts HJ, Bergsma-Kadijk JA, Mourits MJ.

BMC Cancer. 2009 Jan 15;9:23. doi: 10.1186/1471-2407-9-23.

35.

Endotoxin exposure in sewage treatment workers: investigation of exposure variability and comparison of analytical techniques.

Spaan S, Smit LA, Eduard W, Larsson L, Arts HJ, Wouters IM, Heederik DJ.

Ann Agric Environ Med. 2008;15(2):251-61.

36.

Time to stop ovarian cancer screening in BRCA1/2 mutation carriers?

van der Velde NM, Mourits MJ, Arts HJ, de Vries J, Leegte BK, Dijkhuis G, Oosterwijk JC, de Bock GH.

Int J Cancer. 2009 Feb 15;124(4):919-23. doi: 10.1002/ijc.24038.

37.

High percentage of abnormal findings on TVU needs further discussion.

Mourits MJ, van der Velde NM, Arts HJ, de Bock GH.

Br J Cancer. 2006 Oct 23;95(8):1125; author reply 1126-7. No abstract available.

38.

Influence of different cleaning practices on endotoxin exposure at sewage treatment plants.

Visser MJ, Spaan S, Arts HJ, Smit LA, Heederik DJ.

Ann Occup Hyg. 2006 Oct;50(7):731-6. Epub 2006 Jun 16.

PMID:
16782738
39.

Fas and Fas ligand in cyst fluids, serum and tumors of patients with benign and (borderline) malignant ovarian tumors.

Arts HJ, de Jong S, Hollema H, Ten Hoor KA, de Vries EG, van der Zee AG.

Int J Oncol. 2005 Feb;26(2):379-84.

PMID:
15645122
40.

Chemotherapy induces death receptor 5 in epithelial ovarian carcinoma.

Arts HJ, de Jong S, Hollema H, ten Hoor K, van der Zee AG, de Vries EG.

Gynecol Oncol. 2004 Mar;92(3):794-800.

PMID:
14984943
41.

Discovery and evaluation of highly active imidotitanium ethylene polymerisation catalysts using high throughput catalyst screening.

Adams N, Arts HJ, Bolton PD, Cowell D, Dubberley SR, Friederichs N, Grant CM, Kranenburg M, Sealey AJ, Wang B, Wilson PJ, Cowley AR, Mountford P, Schröder M.

Chem Commun (Camb). 2004 Feb 21;(4):434-5. Epub 2004 Jan 14.

PMID:
14765245
42.

A Suzuki coupling based route to 2,2'-bis(2-indenyl)biphenyl derivatives.

IJpeij EG, Beijer FH, Arts HJ, Newton C, de Vries JG, Gruter GJ.

J Org Chem. 2002 Jan 11;67(1):169-76.

PMID:
11777455
43.

Options for modulation of drug resistance in ovarian cancer.

Arts HJ, Van Der Zee AG, De Jong S, De Vries EG.

Int J Gynecol Cancer. 2000 Jan;10(S1):47-52.

PMID:
11240733
44.

[Expression and prognostic value of the drug resistance markers P-gp, Mrp1, Mrp2, and Lrp in ovarian carcinoma].

Katsaros D, Fracchioli S, Arts HJ, de Vries EG, Danese S, Richiardi G, Arisio R, Gordini G, Van der Zee AG, Suurmeijer AJ, Massobrio M.

Minerva Ginecol. 1999 Dec;51(12):463-70. Italian.

PMID:
10767994
45.

Drug resistance-associated markers P-glycoprotein, multidrug resistance-associated protein 1, multidrug resistance-associated protein 2, and lung resistance protein as prognostic factors in ovarian carcinoma.

Arts HJ, Katsaros D, de Vries EG, Massobrio M, Genta F, Danese S, Arisio R, Scheper RJ, Kool M, Scheffer GL, Willemse PH, van der Zee AG, Suurmeijer AJ.

Clin Cancer Res. 1999 Oct;5(10):2798-805.

46.

Heat-shock-protein-27 (hsp27) expression in ovarian carcinoma: relation in response to chemotherapy and prognosis.

Arts HJ, Hollema H, Lemstra W, Willemse PH, De Vries EG, Kampinga HH, Van der Zee AG.

Int J Cancer. 1999 Jun 21;84(3):234-8.

47.

Laparoscopic placement of PAP catheters for intraperitoneal chemotherapy in ovarian carcinoma.

Arts HJ, Willemse PH, Tinga DJ, de Vries EG, van der Zee AG.

Gynecol Oncol. 1998 Apr;69(1):32-5.

PMID:
9570995

Supplemental Content

Support Center